Lv6
1840 积分 2021-10-22 加入
Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non–Small Cell Lung Cancer
3小时前
已完结
Biomarkers of Hyperprogression and Pseudoprogression with Immune Checkpoint Inhibitor Therapy
5天前
已关闭
Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial
17天前
已完结
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
17天前
已完结
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC
1个月前
已完结
Redefining Lung Cancer Therapy - A Long-Awaited Shift in Strategy
1个月前
已完结
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
1个月前
已完结
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial
2个月前
已完结
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial
2个月前
已完结
Permalink Page navigation Title & authors Abstract Conflict of interest statement Comment in Similar articles Cited by Publication types MeSH terms Substances Associated data Related information LinkOut - more resources Clinical Trial Lancet Oncol . 2022 Feb;23(2):220-233. doi: 10.1016/S1470-2045(21)00650-1. Epub 2022 Jan 14
3个月前
已完结
皖公网安备34019202002308
